Moneycontrol Bureau
Shares of Suven Life Sciences rallied 8.6 percent intraday Tuesday on getting three product patents for NCEs in Canada, Japan and Korea.
These product patents are related to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases like alzheimer’s disease, attention deficient hyperactivity disorder, huntington’s disease, parkinson and schizophrenia. These patents are valid through 2030.
With these new patents, Suven has a total of 18 granted patents from Canada, 16 granted patents from Japan, and 16 product patents from Korea.
"These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II," said the company in its filing to the exchange.
At 14:36 hours IST, the scrip of Suven Life Sciences was quoting at Rs 297.65, up Rs 18.10, or 6.47 percent on the BSE.
Posted by Sunil Shankar Matkar
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
